Phase III Adjuvant Melanoma Monotherapy
Research payments
$3,095,512
Through program year 2024, $3,095,512 in research payments was reported against Phase III Adjuvant Melanoma Monotherapy, across 177 payments, paid by E.R. Squibb & Sons, L.L.C..
- Paid by
- E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $119,373 | 23 |
| 2023 | Research | $103,502 | 23 |
| 2022 | Research | $18,926 | 11 |
| 2021 | Research | $556,800 | 36 |
| 2020 | Research | $1,497,681 | 41 |
| 2019 | Research | $799,230 | 43 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Patrick Ott Boston, MA Named on 12 payments
- Omid Hamid Los Angeles, CA Named on 6 payments
- Aimee Kohn Portland, OR Named on 6 payments
- Asim Amin Charlotte, NC Named on 4 payments
- David Spigel Nashville, TN Named on 4 payments
- Shailender Bhatia Seattle, WA Named on 3 payments
- Brendan Curti Portland, OR Named on 3 payments
- Leslie Fecher Ann Arbor, MI Named on 3 payments
- Charles Cowey Dallas, TX Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.